UPDATE: SINTX Strengthens Infection-Prevention Portfolio with Newly Allowed U.S. Patent Covering $30 Billion Antipathogenic Addressable Market

Core Insights - SINTX Technologies has received a Notice of Allowance for a patent application covering its antipathogenic fabric technology, enhancing its competitive advantage and broadening licensing opportunities [1][2][4] - The new patent complements an existing patent for Antipathogenic Fibrous Materials, creating a comprehensive intellectual property (IP) barrier around SINTX's pathogen-inactivation technology [2][3][4] - The company aims to leverage its dual-patent estate to pursue partnerships in medical textiles, wound care, and filtration/PPE sectors, enhancing its commercialization potential [6][7] Intellectual Property Development - The newly allowed method patent strengthens the protection of SINTX's silicon nitride technology platform, covering both the composition and manufacturing processes of its fabrics [4][5] - The dual coverage of composition and method allows SINTX to defend and license various manufacturing and application pathways, crucial for engaging with potential partners [4][5] Market Context - The infection-prevention market is estimated to be around $30 billion, encompassing medical textiles, wound management, filtration/PPE, and healthcare infrastructure, supported by the new patent coverage [6] - Approximately 1 in 31 U.S. hospital patients experience healthcare-associated infections (HAIs), highlighting the demand for effective surface-level infection prevention solutions [7] Scientific Validation - Peer-reviewed studies have demonstrated that silicon nitride can achieve up to ~99.97% reduction of infectious SARS-CoV-2 in laboratory conditions, validating its effectiveness in antipathogenic applications [5]